RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID

<p><strong>Aim.</strong> To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.</p><p><...

Full description

Bibliographic Details
Main Authors: N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2016-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/734
id doaj-f50f798faa444b879e814e36e5526f1d
record_format Article
spelling doaj-f50f798faa444b879e814e36e5526f1d2020-11-24T23:13:45ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-0156414610.1234/1819-6446-2009-6-41-46733RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACIDN. F. Puchinyan0N. V. Furman1A. R. Kiselev2Ya. P. Dovgalevsky3Саратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологииСаратовский научно-исследовательский институт кардиологии<p><strong>Aim.</strong> To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.</p><p><strong>Material and methods.</strong> 200 patients with ACS (aged 56,6±9,2 y.o.) were included in the study. Platelet functional activity during ASA therapy was evaluated with laser aggregometer. ASA resistance was defined if the summarizing index of platelet aggregation (induced with ADP, 5 mμml/l) was 50% or higher during ASA therapy. Observation period was 18±6 months. Atherothrombotic events (unstable angina, myocardial infarction, stroke, cardiovascular death) were considered.</p><p><strong>Results.</strong> Lack ASA response rate was about 12%. Totally 22 repeated atherothrombotic events were registered: 5,6% among ASA sensitive patients and 50% - among ASA resistant patients. Repeated atherothrombotic events were registered in ASA resistance patients during first 14 days. ASA sensitive patients showed repeated atherothrombotic events in some months after ACS. The relative risk of cardiovascular event in ASA resistance patients was 8,92 (CI 95% 4,39; 17,84 р=0,05).</p><p><strong>Conclusion.</strong> The high level of the induced platelet aggregation (proven by laser aggregometry) points to high risk of repeated atherothrombotic events in patients with ACS.</p>http://www.rpcardio.ru/jour/article/view/734острый коронарный синдромантиагрегантыэффективность терапиисердечно-сосудистые осложнения
collection DOAJ
language English
format Article
sources DOAJ
author N. F. Puchinyan
N. V. Furman
A. R. Kiselev
Ya. P. Dovgalevsky
spellingShingle N. F. Puchinyan
N. V. Furman
A. R. Kiselev
Ya. P. Dovgalevsky
RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
Racionalʹnaâ Farmakoterapiâ v Kardiologii
острый коронарный синдром
антиагреганты
эффективность терапии
сердечно-сосудистые осложнения
author_facet N. F. Puchinyan
N. V. Furman
A. R. Kiselev
Ya. P. Dovgalevsky
author_sort N. F. Puchinyan
title RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
title_short RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
title_full RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
title_fullStr RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
title_full_unstemmed RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID
title_sort risk of repeated thrombotic events in patients survived acute coronary syndrome and having laboratory proven resistance to acetylsalicylic acid
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2016-01-01
description <p><strong>Aim.</strong> To evaluate risk of repeated atherothrombotic events in patients survived acute coronary syndrome (ACS) and having poorly reduced platelet aggregation (proven by optical aggregometry) in response to acetylsalicylic acid (ASA) therapy.</p><p><strong>Material and methods.</strong> 200 patients with ACS (aged 56,6±9,2 y.o.) were included in the study. Platelet functional activity during ASA therapy was evaluated with laser aggregometer. ASA resistance was defined if the summarizing index of platelet aggregation (induced with ADP, 5 mμml/l) was 50% or higher during ASA therapy. Observation period was 18±6 months. Atherothrombotic events (unstable angina, myocardial infarction, stroke, cardiovascular death) were considered.</p><p><strong>Results.</strong> Lack ASA response rate was about 12%. Totally 22 repeated atherothrombotic events were registered: 5,6% among ASA sensitive patients and 50% - among ASA resistant patients. Repeated atherothrombotic events were registered in ASA resistance patients during first 14 days. ASA sensitive patients showed repeated atherothrombotic events in some months after ACS. The relative risk of cardiovascular event in ASA resistance patients was 8,92 (CI 95% 4,39; 17,84 р=0,05).</p><p><strong>Conclusion.</strong> The high level of the induced platelet aggregation (proven by laser aggregometry) points to high risk of repeated atherothrombotic events in patients with ACS.</p>
topic острый коронарный синдром
антиагреганты
эффективность терапии
сердечно-сосудистые осложнения
url http://www.rpcardio.ru/jour/article/view/734
work_keys_str_mv AT nfpuchinyan riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid
AT nvfurman riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid
AT arkiselev riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid
AT yapdovgalevsky riskofrepeatedthromboticeventsinpatientssurvivedacutecoronarysyndromeandhavinglaboratoryprovenresistancetoacetylsalicylicacid
_version_ 1725596716022890496